Literature DB >> 12407738

Clinical utility of tumor markers in the management of non-small cell lung cancer.

Dennis E Niewoehner1, Jeffrey B Rubins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12407738     DOI： 10.1385/1-59259-324-0:135

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN： 1543-1894


× No keyword cloud information.
  2 in total

1.  IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer.

Authors:  Jiang-Jiang Li; Ruilei Li; Wenxiang Wang; Baihua Zhang; Xin Song; Chunfang Zhang; Yang Gao; Qianjin Liao; Ya He; Shuo You; Zheqiong Tan; Xiangjian Luo; Yueshuo Li; Min Tang; Xinxian Weng; Wei Yi; Shifang Peng; Shaohui Liu; Ying Tan; Ann M Bode; Ya Cao
Journal:  Mol Oncol       Date:  2018-03-25       Impact factor: 7.449

2.  Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer.

Authors:  Rong Wang; Guoqing Wang; Nan Zhang; Xue Li; Yunde Liu
Journal:  Biomed Res Int       Date:  2013-09-19       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.